Journal of Cognitive Neuroscience
October 1, 2005
Olivia Carter, David C. Burr, John D. Pettigrew et al.
236 citations
A hallucinogenic drug that activates serotonin receptors, psilocybin, impaired healthy volunteers' ability to track moving objects but did not affect their spatial working memory. Blocking the 5-HT2A receptor with ketanserin before psilocybin did not prevent this attentional deficit, pointing to the 5-HT1A receptor as the likely cause. The authors suggest the impairment may stem from a reduced ability to filter out distractions rather than a loss of attentional capacity. Eight participants completed both tasks under placebo, psilocybin, ketanserin, and the combination.
Neuroreport
August 1, 2004
Olivia Carter, John D. Pettigrew, David C. Burr et al.
83 citations
The hallucinogenic drug psilocybin, which activates serotonin receptors, selectively impairs the ability to perceive coherent motion in random dot patterns, a task that relies on high-level global motion detectors, while leaving contrast sensitivity for drifting gratings, mediated by low-level detectors, unaffected. This pattern of visual processing deficits mirrors those seen in schizophrenia, suggesting psilocybin may serve as a pharmacological model for studying psychosis and the neural basis of visual perception.
Journal of Vision
March 17, 2010
Olivia Carter, David C. Burr, John D. Pettigrew et al.
6 citations
A hallucinogenic drug that activates serotonin receptors, psilocybin, impairs the ability to track multiple moving objects but does not affect spatial working memory, indicating a functional separation between these two cognitive processes. Blocking one type of serotonin receptor (5-HT2A) with ketanserin did not prevent this attentional deficit, pointing to the involvement of another receptor (5-HT1A) instead. The impairment may stem from difficulty ignoring distractions rather than a reduction in attentional capacity itself.